Biomarker-based therapy in pancreatic ductal adenocarcinoma: An emerging reality? Review uri icon


MeSH Major

  • Adenocarcinoma
  • Pancreatic Neoplasms


  • © 2017 American Association for Cancer Research. Over the last decade, many of the major solid organ cancers have seen improvements in survival due to development of novel therapeutics and corresponding biomarkers that predict treatment efficacy or resistance. In contrast, favorable outcomes remain challenging in pancreatic ductal adenocarcinoma (PDAC), in part related to the lack of validated biomarkers for patient and treatment selection and thus optimal clinical decision-making. Increasingly, however, therapeutic development for PDAC is accompanied by bioassays to evaluate response and to study mechanism of actions with a corresponding increase in the number of trials in mid to late stage with integrated biomarkers. In addition, blood-based biomarkers that provide a measure of disease activity and allow for minimally invasive tumor analyses are emerging, including circulating tumor DNA, exosomes, and circulating tumor cells. In this article, we review potential biomarkers for currently approved therapies as well as emerging biomarkers for therapeutics under development.

publication date

  • May 15, 2018



  • Review



  • eng

PubMed Central ID

  • PMC5955785

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-16-3169

PubMed ID

  • 29269376

Additional Document Info

start page

  • 2241

end page

  • 2250


  • 24


  • 10